Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Date:8/8/2013

any-sponsored, randomized, placebo-controlled Phase 2 trial of apatorsen in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer. Approximately 180 patients have been randomized into Borealis-1 at 55 clinical sites throughout North America and Europe. The primary endpoint of the trial is overall survival and data are expected to be available in the the second-half of 2014.
  • In August 2013, the Company announced initiation of patient enrollment in the Spruce™ clinical trial. Spruce is an investigator-sponsored, randomized, double-blind, placebo-controlled Phase 2 trial evaluating apatorsen in patients with previously untreated advanced non-squamous NSCLC.
  • In addition to Borealis-1 and Spruce, as part of the ORCA™ (Ongoing Studies Evaluating Treatment Resistance in CAncer) program, apatorsen is currently being evaluated in the following investigator-sponsored, randomized Phase 2 trials across four tumor types. Recent updates to additional ORCA trials are as follows:
  • The Borealis-2™ Trial was initiated in April 2013 and is currently enrolling patients. This investigator-sponsored, randomized, open-label Phase 2 trial is evaluating apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy. Borealis-2 aims to enroll approximately 200 patients.
  • The Cedar™ Trial is an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in previously untreated patients with advanced squamous cell lung cancer. Plans to initiate Cedar were announced in May 2013. The trial aims to enroll approximately 140 patients and is being conducted in the UK.
  • The Rainier™ Trial is an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination wi
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
    3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
    4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    5. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    6. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
    8. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    9. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
    10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
    11. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/1/2015)... FALLS, N.J. , May 1, 2015 CANTEL ... Andrew A. Krakauer , Chief Executive Officer, will be presenting ... at the Encore at the Wynn in Las ... Thursday, May 14, 2015 at 10:00 AM PT/1:00 PM ET. ... during the day. An audio webcast will ...
    (Date:5/1/2015)... , May 1, 2015  Portal Instruments, Inc., ... delivery systems, announced today that Robert Langer, Sc. ... Ph.D., University of Auckland Distinguished Professor have joined the ... to welcome two esteemed biotechnology leaders, Professor Robert ... our team," said Dr. Patrick Anquetil , Chief ...
    (Date:5/1/2015)... -- Thoratec Corporation (NASDAQ: THOR ), a world leader in ... hearts, announced today that Marta Antonucci has joined ... This new Europe -based position is ... North America , including Europe , ... , and reports directly to the Chief Executive Officer. Following ...
    Breaking Medicine Technology:Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 2Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 3Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 4Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3
    ... 1, 2011 Milestone Scientific Inc. (OTCQB: MLSS), the ... the Company filed its 2010 year-end results for the ... Securities & Exchange Commission on Wednesday, March 30, 2011. ... teleconference Monday, April 4, 2011 beginning at 4:15 PM ...
    ... 2011 New data presented today at the 46th ... of the Liver (EASL) demonstrate the antiviral activity of ... both treatment-naive and -experienced patients with chronic genotype-1 (GT1) ... HCV to treat.  Results from SILEN-C1 show a sustained ...
    Cached Medicine Technology:Milestone Scientific Will Host Its 2011 Conference Call on Monday, April 4, 2011 2Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 2Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 3Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 4Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 5Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 6
    (Date:5/2/2015)... Beach, FL (PRWEB) May 02, 2015 ... has selected The Delray Recovery Center as one of ... Center is known in the addiction treatment field for ... staff members to innovate and to continue their educational ... a positive workplace environment, never forgetting their purpose – ...
    (Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand healthcare ... its new healthcare insurance to individuals and small businesses ... System is the nation’s first health insurance system built ... Personal Health Insurance was ZoomCare’s first such filing including ... to review and regulation by the Oregon Insurance Division. ...
    (Date:5/1/2015)... Jusuru International has been awarded the prestigious ... its flagship nutritional supplement, Liquid BioCell™ Life, and the ... new logo, new packaging, new products, and new messaging. ... identify and promote programs that serve as examples of ... Jusuru International for their outstanding accomplishments and contributions to ...
    (Date:5/1/2015)... 2015 Hope For The Warriors® thanks ... For The Warriors® and military families. All American Ford ... For The Warriors®, a national nonprofit dedicated to restoring ... restoring hope for our service members and our military ... Ford collected and matched small autograph fee from fans ...
    (Date:5/1/2015)... Colorado (PRWEB) May 01, 2015 As ... States approaches its 18-month anniversary, many people in the ... been achieved. , According the latest annual report by ... expanded 74 percent in 2014, and reached nearly $3 ... America’s decades-long love affair with cannabis, combined with the ...
    Breaking Medicine News(10 mins):Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 3
    ... Feb. 12 Bunker Hill Community College is ... held a series of events on National Wear Red Day ... disease is the leading cause of death in women. Stickers ... campaign - were handed out to the entire College community, ...
    ... Feb. 12 Medicare now pays for treatments deemed ... that and apply a cost-effectiveness standard set by a ... Research.The Federal Council is modeled after a U.K. board ... This British board approves or rejects treatments using a ...
    ... as likely to show early damage, and study says it,s likely ... who consume two or more cans of soda pop daily are ... evidence of kidney disease, according to a U.S. study. , But ... pop or for people who drink diet soda. , The researchers ...
    ... Slumdog Millionaire show the challenges facing the polio eradication ... Oscar-watchers are getting a short course in polio eradication ... show the status of this paralyzing disease in India ... virus has not been stopped. The Final Inch, ...
    ... ISTA ), today announced it will release fourth quarter and ... a conference call to discuss these results and provide a pipeline ... Date: Thursday, February 19, 2009, ... Internet: www.istavision.com, Domestic dial-in: 866-730-5766, ...
    ... who as children got radiation treatment for Hodgkin,s disease are ... cancer, according to findings from five institutions, including the University ... higher the risk, researchers report. These women are also likely ... is always to get rid of the cancer. Our second ...
    Cached Medicine News:Health News:Bunker Hill Community College Celebrates 'Wear Red Day' 2Health News:2 or More Sodas a Day Boost Women's Kidney Risks 2Health News:Oscar Nominated Films Raise Polio Awareness 2Health News:Pediatric Hodgkin's disease survivors face increased breast cancer risk 2Health News:Pediatric Hodgkin's disease survivors face increased breast cancer risk 3
    ... information to facilitate diagnostic accuracy for appropriate ... sterile, disposable device used to inject fluid ... procedures. The device will measure the pressure ... a digital format. The physician can control ...
    Maxi-Therm® hyper-hypothermia water blankets from Cincinnati Sub-Zero are designed for single-patient use. These blankets are easy to clean, stain resistant and ideal for isolation cases....
    The Neuro-Cool™ System provides pain relief by combining a head wrap with a cold therapy unit for effective migraine treatment....
    The ImmunoWELL Borrelia M Test is an enzyme immunoassay (EIA) for the qualitative and/or semiquantitative detection of Borrelia burgdorferi,IgM antibodies in serum and is used as an aid in the diag...
    Medicine Products: